Quinagolide
 | |
| Clinical data | |
|---|---|
| Trade names | Norprolac |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | G02CB04 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
87056-78-8  |
| PubChem (CID) | 55645 |
| ChemSpider |
2343034  |
| UNII |
80Q9QWN15M |
| KEGG |
D07217 |
| ChEMBL |
CHEMBL290962 |
| Chemical and physical data | |
| Formula | C20H33N3O3S |
| Molar mass | 395.56 g/mol |
| |
| (what is this?) (verify) | |
Quinagolide (INN, BAN) (brand name Norprolac) is a selective D2 receptor agonist that is used to reduce elevated levels of prolactin (hyperprolactinemia).[1] It has also been found to be effective in the treatment of breast pain.[2]
See also
References
- ↑ Antonella Di Sarno; Maria Luisa Landi; Paolo Marzullo; Carolina Di Somma; Rosario Pivonello; Gaetana Cerbone; Gaetano Lombardi; Annamaria Colao (July 2000). "The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas". Clinical Endocrinology. 53 (1): 53–60. doi:10.1046/j.1365-2265.2000.01016.x. PMID 10931080.
- ↑ Alfonso M Pluchinotta (20 April 2015). The Outpatient Breast Clinic: Aiming at Best Practice. Springer. pp. 167–. ISBN 978-3-319-15907-2.
This article is issued from Wikipedia - version of the 11/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.